Compare Eli Lilly And Co (LLY) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Trip.com Group Ltd — how do they compare? Eli Lilly And Co trades at $1,173.98 (market cap $1.04T), while Trip.com Group Ltd trades at $38.81 (market cap $23.75B). The key difference: Eli Lilly And Co is far larger — about 43.8× Trip.com Group Ltd's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Trip.com Group Ltd for 79 Days on average.
| LLY | TCOM | |
|---|---|---|
Market Cap | $1.04T | $23.75B |
Volume | 3,064,878 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $78.96 |
52-Week Low | $799.57 | $37.96 |
Typical Hold Time | 93 Days | 79 Days |
Enterprise Value | $1.09T | $15.91B |
Dividend Yield | 0.59% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Trip.com Group (TCOM) trades at $38.89, up 2.1% with mixed technical signals showing bearish moving averages but oversold RSI conditions. The company demonstrates strong fundamentals with revenue growing from $20.0B in 2022 to $62.4B in 2025, maintaining robust 36.9% net margins. Recent Q2 2026 earnings beat expectations at $1.07 per share versus $0.98 estimate, though regulatory headwinds from Chinese antitrust actions create uncertainty.
The stock presents a compelling value opportunity with low P/E of 7.34 and significant 46% upside to consensus price target of $56.64, supported by 70% analyst buy ratings. However, regulatory pressure on pricing algorithms and geopolitical risks require careful monitoring given the bearish technical setup and recent price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
